Eisai Co Ltd 4523
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Lecanemab Fails to Get EU Marketing Approval; Eisai to Seek Reexamination
-
Biogen's stock stumbles as Alzheimer's drug is rejected by European regulators
-
Eli Lilly's Alzheimer's drug wins FDA approval
-
Eli Lilly's Alzheimer's drug gets backing from FDA advisers
-
Eli Lilly's Alzheimer's drug to face safety, dosing scrutiny from FDA advisers
-
Biogen's stock climbs as first-quarter profit tops estimates, Alzheimer's drug uptake improves
-
Merck and Eisai combination endometrial cancer treatment fails to meet goals in clinical trial
-
Merck, Eisai: Keytruda/Lenvima Combo Fails in 1st-Line Endometrial Cancer Study
Trading Information
- Previous Close Price
- ¥5,497.00
- Day Range
- ¥5,511.00–5,577.00
- 52-Week Range
- ¥4,986.00–8,461.00
- Bid/Ask
- ¥5,537.00 / ¥5,552.00
- Market Cap
- ¥1.57 Tril
- Volume/Avg
- 1.4 Mil / 1.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- 42.15
- Price/Sales
- 2.15
- Dividend Yield (Trailing)
- 2.91%
- Dividend Yield (Forward)
- 2.91%
- Total Yield
- 2.91%
Company Profile
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of a pharmaceutical business and other businesses. The pharmaceutical business is categorized by region, including Japan, Americas, China, Asia, and Europe, Middle East, and Africa. Eisai also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived by its Japanese pharmaceutical business, followed by its Americas pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Large Core
- Total Number of Employees
- 11,067
- Website
- http://www.eisai.co.jp
Comparables
Valuation
|
Metric
|
4523
|
605116
|
4577
|
|---|---|---|---|
Price/Earnings (Normalized) | 42.15 | 30.07 | 11.99 |
Price/Book Value | 1.80 | 4.70 | 0.68 |
Price/Sales | 2.15 | 6.90 | 0.78 |
Price/Cash Flow | 24.42 | 20.39 | 5.80 |
Price/Earnings
4523
605116
4577
Financial Strength
|
Metric
|
4523
|
605116
|
4577
|
|---|---|---|---|
Quick Ratio | 1.72 | 1.29 | 0.80 |
Current Ratio | 2.37 | 2.22 | 2.24 |
Interest Coverage | 22.36 | 163.49 | 103.88 |
Quick Ratio
4523
605116
4577
Profitability
|
Metric
|
4523
|
605116
|
4577
|
|---|---|---|---|
Return on Assets (Normalized) | 3.44% | 14.01% | 5.27% |
Return on Equity (Normalized) | 5.41% | 18.41% | 7.62% |
Return on Invested Capital (Normalized) | 3.92% | 16.29% | 6.69% |
Return on Assets
4523
605116
4577
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Zoetis Inc Class A
ZTS
| Qqnkjjshjp | Lfzr | $86.1 Bil | |||
| Merck KGaA ADR
MKKGY
| Vjyznrfpt | Qbscl | $74.3 Bil | |||
| Haleon PLC ADR
HLN
| Pzckltwh | Zfry | $45.9 Bil | |||
| Viatris Inc
VTRS
| Bxxxlzgp | Ftyd | $13.8 Bil | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Wxlxjftw | Mwqp | $13.2 Bil | |||
| Catalent Inc
CTLT
| Dcvgstzs | Ncwfhy | $11.0 Bil | |||
| Prestige Consumer Healthcare Inc
PBH
| Mckktztc | Zbdcm | $3.4 Bil | |||
| Perrigo Co PLC
PRGO
| Mrlnvcxgj | Tqgw | $3.4 Bil | |||
| Green Thumb Industries Inc
GTBIF
| Rsqsshcq | Ywbtt | $2.4 Bil | |||
| Curaleaf Holdings Inc
CURLF
| Sgnbwxnq | Rgkry | $2.2 Bil |
United States